These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35306635)

  • 41. 2022 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2022 Apr; 18(4):700-789. PubMed ID: 35289055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
    Gauthier S; Leuzy A; Racine E; Rosa-Neto P
    Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Early detection of Alzheimer's disease and dementia prediction in patients with mild cognitive impairment : Summary of current recommendations].
    Rostamzadeh A; Jessen F
    Nervenarzt; 2020 Sep; 91(9):832-842. PubMed ID: 32300816
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology.
    Osborn KE; Alverio JM; Dumitrescu L; Pechman KR; ; Gifford KA; Hohman TJ; Blennow K; Zetterberg H; Jefferson AL
    J Alzheimers Dis; 2019; 71(1):281-290. PubMed ID: 31381510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.
    Blennow K; Dubois B; Fagan AM; Lewczuk P; de Leon MJ; Hampel H
    Alzheimers Dement; 2015 Jan; 11(1):58-69. PubMed ID: 24795085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction and Early Detection of Alzheimer's Dementia: Professional Disclosure Practices and Ethical Attitudes.
    Schweda M; Kögel A; Bartels C; Wiltfang J; Schneider A; Schicktanz S
    J Alzheimers Dis; 2018; 62(1):145-155. PubMed ID: 29439325
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota.
    Li B; He Y; Ma J; Huang P; Du J; Cao L; Wang Y; Xiao Q; Tang H; Chen S
    Alzheimers Dement; 2019 Oct; 15(10):1357-1366. PubMed ID: 31434623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A clinical index to predict progression from mild cognitive impairment to dementia due to Alzheimer's disease.
    Lee SJ; Ritchie CS; Yaffe K; Stijacic Cenzer I; Barnes DE
    PLoS One; 2014; 9(12):e113535. PubMed ID: 25486250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection.
    Risacher SL; Saykin AJ
    Annu Rev Clin Psychol; 2013; 9():621-48. PubMed ID: 23297785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease.
    Kulic L; Unschuld PG
    Curr Opin Neurol; 2016 Dec; 29(6):749-755. PubMed ID: 27805971
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
    van Maurik IS; Vos SJ; Bos I; Bouwman FH; Teunissen CE; Scheltens P; Barkhof F; Frolich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Frisoni GB; Spiru L; Freund-Levi Y; Wallin AK; Hampel H; Soininen H; Tsolaki M; Verhey F; Kłoszewska I; Mecocci P; Vellas B; Lovestone S; Galluzzi S; Herukka SK; Santana I; Baldeiras I; de Mendonça A; Silva D; Chetelat G; Egret S; Palmqvist S; Hansson O; Visser PJ; Berkhof J; van der Flier WM;
    Lancet Neurol; 2019 Nov; 18(11):1034-1044. PubMed ID: 31526625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment.
    Falgàs N; Tort-Merino A; Balasa M; Borrego-Écija S; Castellví M; Olives J; Bosch B; Férnandez-Villullas G; Antonell A; Augé JM; Lomeña F; Perissinotti A; Bargalló N; Sánchez-Valle R; Lladó A
    Eur J Neurol; 2019 Aug; 26(8):1098-1104. PubMed ID: 30793432
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment.
    Frederiksen KS; Nielsen TR; Winblad B; Schmidt R; Kramberger MG; Jones RW; Hort J; Grimmer T; Georges J; Frölich L; Engelborghs S; Dubois B; Waldemar G
    Eur J Neurol; 2021 Jul; 28(7):2147-2155. PubMed ID: 33368924
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.
    Grill JD; Di L; Lu PH; Lee C; Ringman J; Apostolova LG; Chow N; Kohannim O; Cummings JL; Thompson PM; Elashoff D;
    Neurobiol Aging; 2013 Jan; 34(1):62-72. PubMed ID: 22503160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease.
    Forlenza OV; Diniz BS; Teixeira AL; Stella F; Gattaz W
    Braz J Psychiatry; 2013; 35(3):284-94. PubMed ID: 24142092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.